Boston Therapeutics Joins the Biotechnology Innovation Organization (BIO)

LAWRENCE, Mass., March 08, 2018 -- Boston Therapeutics, Inc announces their new participation in MassBIO, an unparalleled network of innovative companies and industry thought leaders dedicated to advancing cutting-edge research and development for patients’ lives improvements.  Expanding operations in the US, the company is participating locally in MassBIO where the vibrant Massachusetts biotechnology industry can help build company value with networking and events, visibility, information resources and access to capital.

Through the recent acquisition of CureDM, the company also enjoys membership in New Mexico BIO.  With BIO participation in two states, Boston Therapeutics will be able to identify and network with the best local partners in the strategic planning of the upcoming clinical trials for both BTI-320 and BTI-420 in 2018. CEO Carl Rausch explains, “Building operations in the US is part of our strategy to leverage our strong relationship with our partners throughout Asia, including China, and we believe MassBIO is a great place to start.  As a small yet global presence, it is our intention to provide unique solutions to the worldwide epidemic of diabetes and its complications.”  

The company intends to participate in upcoming BIO events and form new partnerships as they continue to develop treatments, technology and innovative approaches to diabetes and related pathologies. 

About Boston Therapeutics, Inc.  www.bostonti.com 
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.   

Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Boston Therapeutics, Inc.
Loraine Upham, COO 
Phone: 603-935-9799
Email: [email protected] 
www.bostonti.com